The effectiveness of the Ginkgo special extracts EGb 761 has been scientifically proven in dozens of studies. The data from a current meta-analysis was recently presented by the Canadian Alzheimer researcher Prof. Dr. Serge Gauthier from Quebec in the specialist journal "Clinical Interventions in Aging" (2014: 9 2065-2077) and at a conference of the "International Psychogeriatric Association" IPA in Beijing.
Data from 2,625 patients from seven randomized, placebo-controlled, double-blind studies served as the basis for the analysis. The patients either had Alzheimer's disease, an additional cerebrovascular disease or vascular dementia and took the Ginkgo special extract EGb 761 or placebo over a period of 22 to 52 weeks. The areas of cognition, everyday activities and the overall clinical impression determined by the investigators were compared.
The evaluation of the data showed: The Ginkgo special extract was significantly superior to the dummy drug in all three examined areas. The effects were particularly pronounced in patients with existing neuropsychiatric symptoms.
The positive effects of the ginkgo extract are believed to be due to a reduction in inflammatory processes in the brain. An experimental study by the research group of the Chinese researcher Dr. Yang Liu hin, which was also presented at the IPA conference in Beijing. Mice that received the Ginkgo special extract as a feed additive showed lower inflammation markers and had better learning performance than animals without the feed additive.
These effects could already be seen after two months, but they were only pronounced after five months. Long-term therapy with the Ginkgo special extract could therefore inhibit inflammatory activities in the brain in Alzheimer's patients and thus slow the progression of the disease, was the conclusion of the Chinese scientists (source: Neurotransmitter 2015; 26, 1).
Image: trolltroll / pixelio.de